Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
Viktor von WylPascal BenkertAndré MoserJohannes LorscheiderBernhard F DécardPeter HänniCarmen LienertJens KuhleTobias DerfussLudwig KapposÖzgür YaldizliPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
Our analysis indicates that fingolimod is superior to IFN/GA in preventing disability progression in both relapsing and relapse-free, young, newly diagnosed RRMS patients.